Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0004153 (
atherosclerosis
)
77,401
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The oxidative modification of low density lipoprotein (LDL) may play an important role in the pathogenesis of
atherosclerosis
. LDL can be oxidatively modified in vitro by endothelial cells, mouse peritoneal macrophages, or copper ions. Studies using lipoxygenase inhibitors have suggested that lipoxygenase(s) is required for the cellular modification of LDL [Rankin, S. M., Parthasarathy, S. & Steinberg, D. (1991) J. Lipid Res. 32, 449-456]. We have reexamined the effect of lipoxygenase inhibitors on cellular modification and found that (i) inhibitors specific for
5-lipoxygenase
do not block LDL modification; (ii) inhibitors that block lipoxygenase by donating one electron to the enzyme (reductive inactivation) prevent LDL modification by cells and also modification mediated by copper ions, implying that they act as general antioxidants; (iii) the lipoxygenase inhibitor 5,8,11,14-eicosatetraynoic acid blocks 15-lipoxygenase activity in intact macrophages at concentrations 100 times less than those required to block LDL modification by macrophages; and (iv) 5,8,11,14-eicosatetraynoic acid is cytotoxic at concentrations about twice those required to prevent modification. Furthermore, macrophages and the RECB4 line of endothelial cells modify LDL with similar efficiencies despite dramatic differences in 15-lipoxygenase activity. Thus we conclude that neither
5-lipoxygenase
nor 15-lipoxygenase is required for modification of LDL by cultured cells.
...
PMID:Cellular oxidative modification of low density lipoprotein does not require lipoxygenases. 172 78
In contrast to the well-studied role of
5-lipoxygenase
in the arachidonic acid cascade that occurs in inflammatory cells, the biological role of the related 15-lipoxygenases in the metabolism of free polyenoic fatty acids is far from clear. However, the activity of 15-lipoxygenases with more complex substrates may play a crucial role in the differentiation and maturation of certain cell types and in the oxidative modification of lipoproteins in the early stages of
atherosclerosis
.
...
PMID:Do 15-lipoxygenases have a common biological role? 178 38
Immediately after a cuff-sheathing of rabbit carotid artery, a large number of leukocytes adhered to injured endothelium then infiltrated into the media. These inflammatory responses were followed by an atherosclerotic change, intimal thickening, of the artery. A simultaneous injection of dexamethasone (10 mg/kg i.m.) inhibited the leukocyte accumulation by 74% when evaluated 18 h thereafter. Similarly, 39% inhibition was obtained with the same dose of FR110302, a potent
5-lipoxygenase
inhibitor. On the other hand, the same dose of indomethacin, a cyclooxygenase inhibitor, had little effect on the leukocyte accumulation. The intimal thickening which was evaluated 3 weeks after the cuff-treatment was attenuated by a daily dose (10 mg/kg i.m.) of dexamethasone or FR110302 but not by one of indomethacin. The inhibition by the two former drugs were 91 and 58%, respectively. In vitro, the three drugs in concentrations up to 10 microM hardly affected endothelial adhesion of PMN which was induced by LPS or IL-1. Though 10 microM of FR110302 and indomethacin significantly decreased PMN chemotaxis induced by LTB4, the decreases were less than that at 10 microM dexamethasone. These results confirm a possible linkage between inflammation and
atherosclerosis
, and suggest that
5-lipoxygenase
products contribute to the initiation and development of
atherosclerosis
.
Atherosclerosis
1991 Nov
PMID:Role of inflammatory responses in initiation of atherosclerosis: effects of anti-inflammatory drugs on cuff-induced leukocyte accumulation and intimal thickening of rabbit carotid artery. 181 46
Atherosclerotic plaque formation is accompanied by hyperproliferative events which have many features of an inflammatory response. A high-performance liquid chromatography procedure was developed to analyze the inflammatory prostaglandins, leukotrienes and hydroxyeicosatetraenoic acids (HETEs) produced by aortic segments. Normal rabbit aortas incubated with tritiated arachidonic acid synthesized 12-HETE as the principal lipoxygenase metabolite, and prostacyclin as the major cyclooxygenase product. In contrast, atherosclerotic aortas from both cholesterol-fed and Watanabe Heritable Hyperlipidemic rabbits showed major increases in synthesis of lipoxygenase-derived 15-HETE, which became the predominant eicosanoid in the aortas of both types of rabbit. No leukotrienes or other
5-lipoxygenase
products were detected to the detection limit of 0.5 pmol/cm aorta. 15-HETE, which is chemotactic for smooth muscle cells, mitogenic for endothelial cells, and an inhibitor of prostacyclin synthesis may thus play a role in atherogenesis.
Atherosclerosis
1989 Jan
PMID:Formation of 15-hydroxyeicosatetraenoic acid (15-HETE) as the predominant eicosanoid in aortas from Watanabe Heritable Hyperlipidemic and cholesterol-fed rabbits. 249 11
The evidence presented here favours the view that dietary supplementation with n-3 fatty acids results in attenuated activity of pro-inflammatory leukotrienes formed through the
5-lipoxygenase
pathway in leucocytes. Neutrophil and monocyte chemotaxis seem to decrease, although this may depend on the patient groups studied. n-3 fatty acids increase the proliferative responses of lymphocytes. It is less clear, whether n-3 fatty acids affect other parts of leucocyte function. The possible value of n-3 PUFAs in inflammatory diseases in humans needs to be documented in carefully conducted clinical trials, which also should look carefully for possible side effects. However, the results obtained so far have been promising. The modulating effect of n-3 fatty acids on leucocyte activity-together with their other effects-could be favourable in
atherosclerosis
and coronary disease.
...
PMID:n-3 fatty acids and leucocytes. 265 Jun 91
Macrophages and smooth muscle cells (SMCs) are two of the major reactive cell types in
atherosclerosis
, a disease characterized by uncontrolled proliferation of SMCs. The present study was designed to determine how dietary oils containing gamma-linolenic acid (GLA) (primrose oil [PO]) and long-chain n-3 fatty acids (fish oil) influence the ability of macrophages to modulate SMC DNA synthesis in vitro. Mice were fed one of four diets containing 10% (wt/wt) corn oil (CO), PO, fish oil-CO mix (FC; 9:1, wt/wt), or fish oil-PO mix (FP; 1:3, wt/wt) for 2 weeks. Resident peritoneal macrophages were isolated from these mice and seeded on a semipermeable membrane with a 30-kDa cutoff. Macrophages were preincubated with or without 50 mumol/L indomethacin (a cyclooxygenase inhibitor) or 50 mumol/L L655,238 (a
5-lipoxygenase
inhibitor) for 30 minutes and subsequently cocultured with naive murine aortic SMCs grown on culture dishes. DNA synthesis in SMCs and prostaglandin formation in coculture supernatants were measured at the end of a 39-hour incubation period. SMC DNA synthesis was inhibited by 28% and 60% in PO and FP diets containing 10.1% and 8.2% GLA, respectively, relative to the control CO diet containing no GLA or long-chain n-3 fatty acid. A fourfold increase in the levels of PGE1, a potent antiproliferative eicosanoid derived from GLA, was observed in the PO and FP groups relative to the control CO group.(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:Dietary gamma-linolenic acid modulates macrophage-vascular smooth muscle cell interactions. Evidence for a macrophage-derived soluble factor that downregulates DNA synthesis in smooth muscle cells. 767 Sep 54
Agonist-induced release of arachidonic acid from membrane phospholipids and its oxygenation by specific enzymes to generate bioactive eicosanoids represent an important series of events that is thought to play a pivotal role in both physiologic and pathologic responses. Research during the past year confirmed and extended our knowledge of lipoxygenase activation and assembly of the
5-lipoxygenase
complex in leukocytes. Many of the key enzymes and proteins in the arachidonic acid signaling cascade were identified, and rational drug design is in progress to interact with these targets. The role of transcellular biosynthesis in leukotrienes, lipoxins, and other novel eicosanoids is emerging as an important theme in eicosanoid formation in multicellular events including thrombosis, inflammation, and
atherosclerosis
. Moreover, new bioactions were identified for both leukotrienes and lipoxins. Counterregulatory roles demonstrated for lipoxins suggest that these compounds may serve as endogenous chalones generated via lipoxygenase- and cell-cell interactions.
...
PMID:Eicosanoids in leukocyte function. 937 Dec 62
Cardiovascular disease is the leading cause of morbidity and mortality in westernized populations. Low levels of alpha-tocopherol (AT) are associated with increased incidence of
atherosclerosis
and increased intakes appear to be protective. Recently, we showed that supplementation with AT resulted in significant decreases in monocyte superoxide anion release, lipid oxidation, interleukin-1 beta (IL-1 beta) release, and adhesion to endothelium. The reduction in superoxide and lipid oxidation by AT seemed to be mediated by inhibition of protein kinase C. The aim of this study was to investigate the mechanism(s) by which AT inhibits IL-1 beta release. Potential mechanisms examined included its effect as an antioxidant and its inhibitory effects on protein kinase C and the cyclooxygenase-lipoxygenase pathways. Although AT decreased superoxide release from activated monocytes, superoxide dismutase and catalase had no effect on IL-1 beta release. Also, a similar antioxidant, beta-tocopherol, had no effect on IL-1 beta release. The protein kinase C inhibitor, bisindolylmaleimide, did not inhibit IL-1 beta release from activated monocytes, in spite of AT decreasing protein kinase C activity. Leukotriene B4, a major product of
5-lipoxygenase
, has been shown to augment IL-1beta release. In the presence of AT, a significant reduction in leukotriene B4 and IL-1 beta levels was observed, which was reversed by the addition of leukotriene B4. Similar observations were seen with specific inhibitors of
5-lipoxygenase
. The product of cyclooxygenase, prostaglandin E2, has been shown to inhibit IL-1 beta activity in some systems. However, AT had no significant effect on prostaglandin E2 levels in activated monocytes. In the presence of indomethacin, a cyclooxygenase inhibitor, AT inhibited IL-1 beta activity. Also, AT had no effect on IL-1 beta mRNA levels or stability, suggesting a posttranscriptional effect. Thus, in activated human monocytes, AT exerts a novel biological effect of inhibiting the release of the proinflammatory cytokine, IL-1 beta, via inhibition of the
5-lipoxygenase
pathway.
...
PMID:Alpha-tocopherol decreases interleukin-1 beta release from activated human monocytes by inhibition of 5-lipoxygenase. 1019 45
12/15-Lipoxygenase is a highly regulated lipid-peroxidating enzyme whose expression and arachidonic acid metabolites are implicated in several important inflammatory conditions including airway and glomerular inflammation as well as
atherosclerosis
. Tissue expression of the original 12/15-lipoxygenase is well characterized in reticulocytes, eosinophils, airway epithelial cells, and monocytes/macrophages and is likely in other cell systems and tissues under specific conditions. The physiologic role of this family of enzymes is dependent on the context in which it is expressed. In general, the arachidonic acid metabolites antagonize inflammatory responses and counteract the proinflammatory effects of the
5-lipoxygenase
pathway. However, certain diHETEs are associaled with pro-inflammatory effects, specifically neutrophilic and eosiniphilic chemotaxis. The direct action of these enzymes on complex lipids and cellular membranes also links them to such significant process as reticulocyte maturation, LDL oxidation in
atherosclerosis
and pulmonary host defenses. The availability of new specific inhibitors and murine lines that lack expression of the homologous 12-lipoxygenase will allow confirmation of many of these effects with in vivo models of inflammation.
...
PMID:The arachidonate 12/15 lipoxygenases. A review of tissue expression and biologic function. 1043 60
In a previous paper we gave evidence that chronic oral defibrotide antagonizes the noxious effect of developing
atherosclerosis
in the cardiovascular system. In the present paper we give evidence that defibrotide is still capable of exerting beneficial effects on cardiovascular function once
atherosclerosis
is established. In fact, there was statistically significant amelioration by defibrotide infusion in the following, all of which were hampered by established
atherosclerosis
: in rabbit aorta relaxation to acetylcholine, prostaglandin E2, and 6-keto-prostaglandin F1alpha generation from rabbit aortas, rabbit heart left ventricular end-diastolic pressure, coronary perfusion pressure, and left ventricular developed pressure, vasopressor activity of acetylcholine and endothelin-1 on coronary perfusion pressure, and 6-keto-prostaglandin F1alpha generation from the rabbit heart. Since prostacyclin takes part in NO generation, is cellular protective, and inhibits
5-lipoxygenase
product synthesis, its increase, caused by defibrotide, could explain defibrotide cardioprotective activity. Prostacyclin activity could be backed by prostaglandin E2, another cardioprotective prostaglandin.
...
PMID:Defibrotide normalizes cardiovascular function hampered by established atherosclerosis in the rabbit. 1068 32
1
2
3
4
5
6
7
8
9
10
Next >>